Ana Paula Anzolin

Mr. Ana Paula Anzolin


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Medical Gas Research
Verified
Journal Article
Open access
AAAna Paula Anzolin
Ana Paula Anzolin
NSNíncialucca da Silveira-Kaross
Níncialucca da Silveira-Kaross
CBChariseDallazem Bertol
ChariseDallazem Bertol
Acute or chronic inflammatory reactions aim to control lesions, resist to pathogens attack and repair damaged tissue. The therapeutic administration of ozone known as ozone therapy appears as a possible treatment for tissue repair, as it promotes the healing of wounds. It has bactericidal, antiviral and antifungal properties and has been used as a therapeutic resource to treat inflammation. The objective was to carry out an integrative review regarding the use of ozonated oil in acute and chronic inflammations. The keywords "ozone therapy," "inflammation" and "ozone" were used in the Portuguese, Spanish and English languages. The paper selection was based on inclusion and exclusion criteria. In total, 28 articles were selected. It has been seen that ozonated oil is effective in healing cutaneous wounds. The beneficial effects are due to the healing of wounds, due to the reduction of microbial infection, debridement effect, modulation of the inflammatory phase, stimulation to angiogenesis as well as biological and enzymatic reactions that favor the oxygen metabolism, improving the wound cicatrization. In addition to promoting healing, ozonated oil reduces symptoms related to skin burns, prevents post-lesion hyperpigmentation, and reduces the pain of aphthous ulcers. Therefore, ozonated oil represents an effective and inexpensive therapeutic alternative that must be implanted in the public health system.

1 October 2023 in Medical Gas Research
Verified
Journal Article
Open access
MSMaria Emilia Gadelha Serra
Maria Emilia Gadelha Serra
JBJosé Baeza-Noci
José Baeza-Noci
CACarmen Verônica Mendes Abdala
Carmen Verônica Mendes Abdala
MLMarilia Moura Luvisotto
Marilia Moura Luvisotto
CBCharise Dallazem Bertol
Charise Dallazem Bertol
AAAna Paula Anzolin
Ana Paula Anzolin
Ozone therapy (OT), a medical procedure, has been showing good results during the coronavirus disease (COVID-19). We aimed to build an evidence and gaps map (EGM) of OT in the COVID-19 ranking the articles found according to levels of evidence and outcomes. The EGM brings bubbles of different sizes and different colors according to the articles. The OT intervention used was major or minor autohemotherapy, rectal insufflation and ozonized saline solution. EGM was based on 13 clinical studies using OT for COVID-19 involving a total of 271 patients. We found 30 outcomes related to OT in COVID-19. Our EGM divided the outcomes into six groups: 1-clinical improvement; 2-hospitalization; 3-inflammatory, thromboembolic, infectious, or metabolic markers; 4-radiological aspects, 5-viral infection and 6-adverse events. Major autohemotherapy was present in 19 outcomes, followed by rectal insufflation. Improvement in clinical symptoms of COVID-19, improvement of respiratory function, improvement of oxygen saturation, reduction in hospital internment, decrease in C-reactive protein, decrease in ferritin, decrease in lactate dehydrogenase, decrease in interleukin 6, decrease in D-dimer, radiological improvement of lung lesions and absence of reported adverse events were related in the papers. The most commonly used concentrations of OT in major autohemotherapy and in rectal insufflation were 40 μg/mL and 35 μg/mL, respectively. Here, we bring the first EGM showing the efficacy and safety of OT in the treatment of COVID-19. OT can be used as integrative medical therapy in COVID-19 at a low cost and improve the health conditions of the patients.

4 May 2022 in Psychiatry Research
Verified
Journal Article
Closed access
AAAna Paula Anzolin
Ana Paula Anzolin
JFJacson Gabriel Feiten
Jacson Gabriel Feiten
GBGiovana Bristot
Giovana Bristot
GPGabriela Maria Pereira Possebon
Gabriela Maria Pereira Possebon
MFMarcelo Pio de Almeida Fleck
Marcelo Pio de Almeida Fleck
MKMarcia Kauer-Sant’aNna
Marcia Kauer-Sant’aNna

21 April 2024 in Psychiatry Research
Verified
Journal Article
Closed access
AAAna Paula Anzolin
Ana Paula Anzolin
DBDaniel Prates Baldez
Daniel Prates Baldez
BMBruno Braga Montezano
Bruno Braga Montezano
FKFlavio Kapczinski
Flavio Kapczinski
PAPaulo Belmonte de Abreu
Paulo Belmonte de Abreu
MKMárcia Kauer-Sant'ANna
Márcia Kauer-Sant'ANna

1 May 2021 in Complementary Therapies in Clinical Practice
Verified
Journal Article
Closed access
AAAna Paula Anzolin
Ana Paula Anzolin
DCDiego da Silva Collares
Diego da Silva Collares
RSRenato Tadeu dos Santos
Renato Tadeu dos Santos
APAdriano Pasqualotti
Adriano Pasqualotti
LRLuciana Grazziotin Rossato-Grando
Luciana Grazziotin Rossato-Grando
CBCharise Dallazem Bertol
Charise Dallazem Bertol

23 December 2025 in The BRICS Health Journal
Verified
Journal Article
Open access
GFGiovanny Vinícius Araújo de França
Giovanny Vinícius Araújo de França
ELEvandro de Oliveira Lupatini
Evandro de Oliveira Lupatini
RRRodrigo Theodoro Rocha
Rodrigo Theodoro Rocha
RTRafaela de Cesare Parmezan Toledo
Rafaela de Cesare Parmezan Toledo
GFGraziella Santana Feitosa Figueiredo
Graziella Santana Feitosa Figueiredo
FNFernanda De Negri
Fernanda De Negri
This study aimed to assess the implementation of the Brazilian National Program for Genomics and Precision Public Health (GenBR) over its initial five years, identifying key achievements, challenges, and lessons for integrating genomics into public health systems in low- and middle-income countries (LMICs). Established by Ministerial Ordinance GM/MS No. 1,949 on August 4, 2020, GenBR aims to lay the foundation for genomics and precision health within Brazil’s Unified Health System. Its primary goals include advancing science and technology countrywide, fostering the development of a national genomics industry, and conducting proof-ofconcept studies to assess the practical application of precision health in public healthcare. By August 2025, over 250 research projects had been funded in 19 of the country’s 27 federative units, across a range of areas, including oncological, rare, cardiovascular, infectious, neurological, and non-communicable diseases, as well as population genomics and precision health. Financial investments had exceeded BRL 1 billion, funding the sequencing of 67,000 samples. Nine large-scale genomics research projects associated with the Program have contributed to generating whole-genome data from 45,910 individuals. Moreover, four public calls have selected 209 research projects led by science and technology institutions located across all regions of Brazil. GenBR offers key lessons for LMICs seeking to implement genomics in public health, particularly in contexts marked by population diversity, infrastructure asymmetries, and fiscal constraints. Findings highlight the importance of sustained political commitment, inclusive governance, and long-term planning for building national genomic capacity and advancing health equity.